chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I don?t believe this is related to the vaccine.  I am having troubles with shortness of breath due to sinus blockage.  It has been going on for a few months and started during the season allergy season/spring bloom.
Extreme fatigue, headache, chest pain. Had to call in sick to work because of extreme side effects.
Patient was 17 years of age and 9 months when the Moderna vaccine was administered. Vaccine licensed for 18 years of age and older. No adverse reaction reported by patient at this time.
From employer: "Reaction:  Vaccine date 1/25 at approximately 1pm.  On Tuesday  afternoon 1/26 employee had body aches and left work early.  She was PCR tested and POC tested for COVID as that is our routine testing day for all staff.  Both tests came back negative.  On Wednesday employee had severe body aches and a temp of 104 which did not break until Friday.  Additional symptoms were severe headache and severe fatigue.  She attempted to drive to the Drs on Sunday but had a car accident which put her in the Emergency room where the Doctor determined that there were no infections present and the symptoms were related to a reaction from the Vaccine."  Spoke to pt on 2/1/21 and pt reported feeling better.
Pfizer vaccine administered on R arm. Patient developed burning sensation of distal extremities (L>R), described as  the feeling of "hot sauce on skin" a day after vaccination. She also reported the sensation that her 4th and 5th digit of left foot was immobile, but motor strength was intact.  OTC NSAIDs did not help relieve symptoms. Symptoms persisted for two weeks, and eventually self resolved.
hallucinating; movement was not like that of a young person; She couldn't balance.; This spontaneous case was reported by a physician and describes the occurrence of HALLUCINATION (hallucinating) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 25-Jan-2022, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Jan-2022, the patient experienced HALLUCINATION (hallucinating) (seriousness criterion medically significant), DYSKINESIA (movement was not like that of a young person) and BALANCE DISORDER (She couldn't balance.). At the time of the report, HALLUCINATION (hallucinating), DYSKINESIA (movement was not like that of a young person) and BALANCE DISORDER (She couldn't balance.) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was  provided. It was mentioned that the patient had been seen by doctors and was told to observe. The patient had two doses of vaccines and mentioned that on the same day, patient was not the same person. Patient couldn't walk well, and became weak the next day. It was reported that the patient has still having all the symptoms. No treatment medication information was provided  Company comment: This spontaneous case concerns a 26-year-old female patient with no medical history reported, who experienced the serious (medically significant) unexpected event of Hallucination, and associated events of Dyskinesia and Balance disorder, on the day after receiving the second dose of mRNA- 1273 vaccine. The patient had experienced Gait inability after the first dose of mRNA- 1273 vaccine, which was ongoing at the time of the report, but it is uncertain if the symptom worsened after the second dose. The patient visited a physician, and expectant management was decided. However, no further clinical information was provided. The benefit-risk relationship of mRNA- 1273 vaccine is not affected by this report.   This case was linked to MOD-2022-497979 (Patient Link).   Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns a 26-year-old female patient with no medical history reported, who experienced the serious (medically significant) unexpected event of Hallucination, and associated events of Dyskinesia and Balance disorder, on the day after receiving the second dose of mRNA- 1273 vaccine. The patient had experienced Gait inability after the first dose of mRNA- 1273 vaccine, which was ongoing at the time of the report, but it is uncertain if the symptom worsened after the second dose. The patient visited a physician, and expectant management was decided. However, no further clinical information was provided. The benefit-risk relationship of mRNA- 1273 vaccine is not affected by this report.
MALAISE; VOMITING; HEADACHE; This spontaneous report received from a consumer concerned multiple patients. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient experienced malaise, vomiting, and headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the vomiting, headache and malaise was not reported. This report was non-serious. This report was associated with a product quality complaint: 90000295817. The suspected product quality complaint has been confirmed to be voided (did not meet pqc criteria as this report indicates it is a follow up for identified adverse events for multiple unnamed patients post vaccination. There is no product quality issue or allegation regarding vaccine efficacy in the information reported). The case does not meet the definition for a product quality complaint (pqc) or explicitly allege a potency issue based on the PQC evaluation/investigation performed. This case is a duplicate of 20230910756. This case, from the same reporter is linked to 20220926249.
Infectious mononucleosis; This spontaneous case was reported by a pharmacist and describes the occurrence of INFECTIOUS MONONUCLEOSIS (Infectious mononucleosis) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Mar-2021, the patient experienced INFECTIOUS MONONUCLEOSIS (Infectious mononucleosis). At the time of the report, INFECTIOUS MONONUCLEOSIS (Infectious mononucleosis) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Anaphylactic reaction; This case was reported by a consumer via call center representative and described the occurrence of anaphylactic reaction in a adult female patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   Co-suspect products included PNEUMOCOCCAL VACCINE (PNEUMONIA VACCINE) for prophylaxis.   On an unknown date, the patient received Influenza vaccine Quadrivalent unspecified season and PNEUMONIA VACCINE. On an unknown date, unknown after receiving Influenza vaccine Quadrivalent unspecified season, the patient experienced anaphylactic reaction (serious criteria GSK medically significant). On an unknown date, the outcome of the anaphylactic reaction was unknown.   The reporter considered the anaphylactic reaction to be related to Influenza vaccine Quadrivalent unspecified season.  Additional details were provided as follows: The age at vaccination was not reported. The reporter did not have Lot number or expiry date or brand name of flu shot. The patient had anaphylactic reactions to flu and pneumonia shots. The reporter considered the anaphylactic reaction to be related to PNEUMONIA VACCINE. The reporter did not consent to follow up.
A report was received from a health care professional on 16Oct02, concerning a 22 month old male vaccinee who was inadvertently administered 0.25ml IM into the vastus lateralis on the 15Oct02. On 15Oct02, the vaccinee suffered a medication error by receiving 0.25ml Fluvirin into the vastus lateralis. The vaccinee had not experienced any adverse events at the time of the report but was being closely monitored. There was insufficient information to determine the reporter's causality assessment. PJP200200609, PJP200200671, PJP200200670, PJP200200669, PJP200200668, PJP200200667, PJP200200666, PJP200200664, PJP200200662, PJP200200663.
Seen employee health office 12/10/13 (L) deltoid tender. Small amt redness and swelling upper forearm - afebrile - improving when seen.
Undefined allergic reaction; Initial information received on 01-Oct-2020 regarding an unsolicited valid non-serious case received from a non-healthcare professional (consumer).  This case involves an patient of unknown age who experienced undefined allergic reaction (hypersensitivity), after receiving  INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] .  The patient's past medical history, concomitant disease or risk factor, medical treatment(s), vaccination(s), family history and concomitant medications were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE (batch number and expiration date were not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious undefined allergic reaction to a biological or med (hypersensitivity) (unknown latency) following the administration of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE.  No laboratory data was reported.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome was not reported for the event hypersensitivity.  There will be no information on the batch number for this case.
Dizziness, Myalgia, Fever, malaise, pain in injection arm Narrative:
3/22/21: Swollen arm, hot to touch, arm swelled; fever,chills, Lupus rash on the abdomen (like welts), Body aches like a Lupus flare. Note- had sore arm for those several days but got worse on 3/22/21. Took Tylenol. After a couple days was fine.   3/27/21 sores appeared on the abdomen, they look like big pimples, approx 4, and one on the chest  3/31/21 All of a sudden woke up in the morning with same issues as 3/22/21 and the sores are still there on the abdomen and chest. The one on the chest has started to go down. 3/31/21 extremely achy, hard to move.
12 hours post vaccination - Rigors  22 hours post vaccination - Nausea, syncope, loss of consciousness for ~ 1 minute   Treatment - Tylenol  Observed by husband (physician)
I got sick a week after I had flu shot; Initial information received on 06-Nov-2020 regarding an unsolicited valid non-serious case received from a patient.  This case involves a patient of unknown age who got sick (illness) a week after had flu shot, while the patient received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.   On an unknown date, the patient received an unknown dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number, route and administration site unknown) for prophylactic vaccination.  On an unknown date, the patient got sick a week after had flu shot (illness) following the administration of INFLUENZA VACCINE.  It was not reported if the patient received a corrective treatment. The event outcome was reported as unknown.  There will be no information available on the batch number for this case.
bulging carotid artery/artery was swollen/2 occlusions in left side of the neck; swelling on left side of the body; bloody nose; felt like i developed aneurysm/felt like I developed clots in lymph nodes; Possible infection after 2nd dose; developed swollen lymph nodes in left neck/trouble with left lymph node.; This spontaneous case was reported by a consumer and describes the occurrence of CAROTID ARTERY OCCLUSION (bulging carotid artery/artery was swollen/2 occlusions in left side of the neck) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.    On 01-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2021, the patient experienced CAROTID ARTERY OCCLUSION (bulging carotid artery/artery was swollen/2 occlusions in left side of the neck) (seriousness criterion medically significant), SWELLING (swelling on left side of the body), EPISTAXIS (bloody nose), FEELING ABNORMAL (felt like i developed aneurysm/felt like I developed clots in lymph nodes), INFECTION (Possible infection after 2nd dose) and LYMPHADENOPATHY (developed swollen lymph nodes in left neck/trouble with left lymph node.). The patient was treated with CEFALEXIN (CEPHALEXINE) ongoing since an unknown date for Infection, at an unspecified dose and frequency and CORTICOSTEROIDS at an unspecified dose and frequency. At the time of the report, CAROTID ARTERY OCCLUSION (bulging carotid artery/artery was swollen/2 occlusions in left side of the neck), SWELLING (swelling on left side of the body), EPISTAXIS (bloody nose), FEELING ABNORMAL (felt like i developed aneurysm/felt like I developed clots in lymph nodes), INFECTION (Possible infection after 2nd dose) and LYMPHADENOPATHY (developed swollen lymph nodes in left neck/trouble with left lymph node.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ultrasound scan: 2 occlusion in left side of the neck.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Company comment: This case concerns a 39 year old female with no relevant medical history who experienced serious unexpected event of carotid artery occlusion on May2021 after the second dose of Moderna Covid 19 vaccine on 01May2021. Rechallenge was not applicable. The benefit-risk relationship is not affected by this report.   This case was linked to MOD-2021-333474 (Patient Link).; Sender's Comments: This case concerns a 39 year old female with no relevant medical history who experienced serious unexpected event of carotid artery occlusion on May2021 after the second dose of Moderna Covid 19 vaccine on 01May2021. Rechallenge was not applicable. The benefit-risk relationship is not affected by this report.
1 of 2 pts vaxed from the same lot# who exp an inj site rxn;pt exp erythema & swelling of entire upper arm from the elbow to the shoulder;seen in ER treated w/Pred;recovered;pt recvd a dose of pneumococcal vax 5yrs ago
red deltoid muscle just below injection site; Swollen; sore; somewhat itchy; This is a spontaneous report from a contactable consumer or other non-health care professional (patient). A 62-years-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EN6202), via an unspecified route of administration (at the age of 62-years), administered in arm left on 02Mar2021 at 17:30 as dose 1, single for COVID-19 immunization. The patient medical history was not reported. Concomitant medica-tions included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfeta-mine sulfate (ADDERALL) taken as 30mg, sertraline hydrochloride (ZOLOFT), clonazepam (KLONOPIN), zinc (ZINC), colecalciferol (D) taken for an unspecified indication, start and stop date were not report-ed. The patient did not receive any other vaccine in four weeks. Patient does not have covid prior vaccination and has not been tested for covid post vaccination. The vaccination facility type was reported as other. The patient previously took opioids and experienced known allergies. On 11Mar2021 at 20:00, the patient experienced red deltoid muscle just below injection site, swollen, sore, somewhat itchy. The treatment was not received for all the adverse events. The clinical outcome for all the events was reported as not recovered.   No follow-up attempts are possible. No further information is expected.
nausea; fatigue; chills; headache; feeling flushed; thinking about not having her 2nd dose; This is a spontaneous report received from a contactable consumer via Pfizer-sponsored program. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE,Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as Unk,single for covid-19 immunization.The patient medical history and concomitant medications were not reported.The patient experienced nausea, fatigue, chills, headache,feeling flushed and thinking about not having her 2nd dose on an unspecified date.The patient wanted to know whether she should still get her 2nd dose or not because she has read information that getting the vaccine after recovering from previous Covid infection would act as a booster since she already have developed some antibodies after being infected with the virus.  Follow-up attempts are completed. No further information is expected.
I woke up that night I couldn't lay on my left arm I was nauseous and in major pain I couldn't move my left arm & I couldn't even function on my left side I felt crappy the next day I stayed in bed for almost 5 days with fever nausea vomiting & diarrhea & body aches.
PATEINT REQUESTED 3 DOSE SERIES WE GAVE HER 2 DOSE SERIES
This is a spontaneous report from two contactable nurses via a Pfizer sales representative. The nurses reported similar events for 3 patients. This is the first of 3 reports. A patient of unspecified age, gender and ethnicity received the first dose of TRUMENBA (lot M13066) via an unspecified route of administration, on unknown date, at single dose. Relevant medical history and concomitant medications were not reported. On unknown date the patient experienced faint redness and swollen at sight, fever at 101 F, stomach pain, vomiting, dizzy, severe headache, severe soreness of arm and she was nauseous. The outcome of the events was unknown. No follow up attempts possible. No further information expected.
Patients were administered Moderna vaccine booster beyond 30 day use by date, stored in refrigerator; Patients were administered Moderna vaccine booster beyond 30 day use by date, stored in refrigerator; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patients were administered Moderna vaccine booster beyond 30 day use by date, stored in refrigerator) and PRODUCT STORAGE ERROR (Patients were administered Moderna vaccine booster beyond 30 day use by date, stored in refrigerator) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.    On 14-Feb-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 14-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patients were administered Moderna vaccine booster beyond 30 day use by date, stored in refrigerator). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Patients were administered Moderna vaccine booster beyond 30 day use by date, stored in refrigerator). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patients were administered Moderna vaccine booster beyond 30 day use by date, stored in refrigerator) and PRODUCT STORAGE ERROR (Patients were administered Moderna vaccine booster beyond 30 day use by date, stored in refrigerator) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The  concomitant medications on use were not provided.  It was reported that vial was initially stored in the refrigerator on 13 Jan 2022 and the vial did not undergo any temperature excursions.  No treatment information was provided.   This case was linked to MOD-2022-482141 (Patient Link).
On 7/13/10 he developed a red, tender bump on (L) thigh progressing to 4" diameter-red-hot-tender to touch. This happened previously on 9/28/07 when he received last DTAP booster but she did not report the "goose-egg" sized bump lasting 7 days.
Herpes Zoster; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently 66 year old female patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications.   In September 2016, the patient was vaccinated with a dose of zoster vaccine live (ZOSTAVAX) (strength, dose number, lot#, expiration date and route were not specified) for the long-term prevention of shingles and zoster-related conditions.  On an unspecified date, the patient experienced Herpes Zoster.  On an unspecified date, the patient was treated by a healthcare provider for Herpes Zoster. The outcome of the event was not reported. The reporter considered the Herpes Zoster to be related to zoster vaccine live (ZOSTAVAX).   Additional information has been requested.
Shingles; This case was reported by a consumer via  interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, 2 weeks after receiving Shingles vaccine, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingles vaccine.  Additional details were reported as follows: This case was reported by the patient for himself or herself. The age at vaccination was not reported. The patient got shingles shot and 2 weeks later got shingles. The patient stated that according to the doctor you cant get shingles from the shot, its a dead virus patient felt lucky.
This case was reported by a healthcare professional and described the occurrence of injection site cellulitis in a 5-year-old female subject who was vaccinated with diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Infanrix, GlaxoSmithKline) for prophylaxis. The subject had no pre-existing medical conditions. There were no concurrent medications. On 14 August 2006 the subject received 5th dose of Infanrix, intramuscularly, in the left thigh (lot AC14B033AA). On 16 August 2006, 2 days after vaccination with Infanrix, the subject experienced injection site cellulitis, injection site redness, injection site warmth and swelling injection site. The subject was seen at a physician's office. The healthcare professional considered the events were clinically significant (or requiring intervention). At the time of initial reporting, 17 August 2006, the events were ongoing. The healthcare professional considered the events were probably related to vaccination with Infanrix. Follow-up information received on 06 September 2006 indicated that the events completely resolved by 20 August 2006. The reporter considered the events to be  related to treatment with Infanrix.
Pt received immunization in left arm. Immediately had a pain that went up the left side of neck and into head. She then developed a 10/10 headache, photophobia, and vertigo. Per her report "This has triggered a migraine" although it was more intense and atypical for migraine. BP was measured in right arm at 175/120. Pt had received Dose 1 with no issues. Patient was monitored for 45 minutes in the vaccine clinic over which time her BP improved slightly and her pain reduced. At the time she left clinic, she was able to ambulate, answer questions, and had no neurological deficits during the event.